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Our aim was to determine the incidence of type 2 diabetes mellitus in a nation-wide population based 
cohort from Spain (di@bet.es study). The target was the Spanish population. In total 5072 people older 
than 18 years,were randomly selected from all over Spain). Socio-demographic and clinical data, survey 
on habits (physical activity and food consumption) and weight, height, waist, hip and blood pressure 
were recorder. A fasting blood draw and an oral glucose tolerance test were performed. Determinations 
of serum glucose were made. In the follow-up the same variables were collected and HbA1c was 
determined. A total of 2408 subjects participated in the follow-up. In total, 154 people developed 
diabetes (6.4% cumulative incidence in 7.5 years of follow-up). The incidence of diabetes adjusted for 
the structure of age and sex of the Spanish population was 11.6 cases/1000 person-years (IC95% = 11.1–
12.1). The incidence of known diabetes was 3.7 cases/1000 person-years (IC95% = 2.8–4.6). The main 
risk factors for developing diabetes were the presence of prediabetes in cross-sectional study, age, male 
sex, obesity, central obesity, increase in weight, and family history of diabetes. This work provides data 
about population-based incidence rates of diabetes and associated risk factors in a nation-wide cohort 
of Spanish population.
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Type 2 diabetes mellitus is one of the most serious health problems of our time. Data from numerous studies agree 
on the continuous growth of its incidence and prevalence rates throughout the world, with unacceptable human, 
social, and economic costs. Diabetes has become one of the main causes of cardiovascular disease, blindness, 
non-traumatic amputations of the lower limbs, kidney failure, and death throughout the world1. In addition, its 
association with the presence of cancer has recently been demonstrated2. Therefore, diabetes is a major challenge 
to public health in all countries. Understanding its epidemiology becomes supremely important for both deter-
mining the health status of the population and planning resources for their care, early diagnosis, and prevention.
The increase in the prevalence of diabetes in the world is multifactorial, and can be partly attributed to popu-
lation aging, higher survival of people with diabetes due to improved medical care, and changes in lifestyle linked 
to increased urbanisation with sedentary behaviour and unhealthy eating profiles leading to increased obesity1. 
The impact of changes in lifestyle is greater in low income countries3.
A substantial proportion of people with diabetes are undiagnosed. In Europe, this group represents 37.9% of 
total diabetes, which, although one of the lowest in the world, means that 22 million people are at an increased 
risk of developing cardiovascular diseases1. In Spain, the di@bet.es study found that nearly half of the detected 
cases were undiagnosed diabetes4.
Most nationwide European studies on diabetes incidence are based on health service registries, and have 
reported incidences between 3 and 6 cases/1000 person-years5,6. However, as far as we know, there are no 
nation-wide population-based incidence studies on diabetes diagnosed by oral glucose tolerance test (OGTT).
Type 2 diabetes is a potentially preventable disease7,8, and the studies on its incidence have led to examination 
of the variables associated with a greater risk for developing this disease. Type 2 diabetes is a polygenic disease 
very influenced by environmental factors and, therefore, it is necessary to perform specific population-based inci-
dence studies, as recommended by the International Diabetes Federation (IDF)9. Of special interest are the stud-
ies at national level, which include results about the differences among natural populations and are necessary for 
national health systems to implement screening and prevention programs as basic tools to prevent the epidemic.
The di@bet.es study was the first national study in Spain designed with the objective of determining the prev-
alence and incidence of diabetes by OGTT. The results of the cross-sectional study were published in 20124. The 
objective of the present study was to describe the incidence of diabetes in Spain through the re-evaluation of this 
cohort, as well as to examine the main risk factors related to development of diabetes.
Results
The main characteristics in the cross-sectional study of the subjects included and non-included in the incidence 
study are shown in Table 1. Men participated less than women and the re-evaluated subjects were one year older 
and had a slightly higher fasting glucose (0.06 mmol/L) than the non-participants. Participants presented more 
frequently a family history of diabetes, more adherence to the Mediterranean diet, and lower frequency of current 
smoking (more ex-smokers in this group). The rest of the variables studied were similar in both groups.
In total, 156 people developed diabetes over the 7.5 year follow-up, which yields a 6.5% cumulative incidence. 
The raw incidence rate in the sample was 8.5 per 1000 person-years (IC95% = 7.3–10.1) (Table 2).
The estimated incidence of diabetes adjusted for the age and sex structure of the Spanish population and the 
form of detection of diabetes was of 11.6 cases/1000 person-years (IC95% = 11.1–12.1). The incidence of known 
diabetes was 3.7 cases/1000 person-years (IC95% = 2.8–4.6) and, therefore, the incidence of unknown diabetes 
was 7.9 cases/1000 person-years (IC95% = 5.3–8.1).
As expected, the incidence of diabetes increased with age and was higher among men (13.4 cases/1000 
person-years IC95% = 12.6–14.2) than among women (9.9 cases/1000 person-years 95% CI = 9.3–10.4) adjusted 
for the form of detection of diabetes. Nevertheless, among people older than 75 years there was no difference 
between sexes (Fig. 1).
The OR of developing diabetes was nearly 3-fold higher among men that among women (OR = 2.7 (1.6–4.5)), 
adjusted for all the other variables studied (Table 2).
Both impaired fasting glucose (IFG) and impaired glucose tolerance (IGT), isolated or in combination, 
were risk factors associated with diabetes. There was a significant risk gradient IGT < IFG < IGT + IFG (P for 
trend < 0.0001) in addition to a significant interaction with sex (P = 0.02).
The presence of obesity and central obesity were related to the risk of diabetes, but overweight (BMI between 
25 and 30 Kg/m2) did not reach significance; although there was a gradient in risk, as shown by the P for trend 
significant (Table 2). Family history of diabetes also contributed to the risk, doubling the incidence. High blood 
pressure, physical activity, the score of adherence to the Mediterranean diet, and dyslipidemia yielded not signif-
icant associations neither in the monovariant nor in the adjusted models (data not shown).
Since there was an interaction between the presence of dysglycemia (IFG and/or IGT) and sex in the explana-
tion of the risk of diabetes (p < 0.0001), we performed a stratified analysis separating each sex to reveal the inter-
action. The incidence of diabetes in normoglycemic men (7.2 cases/1000 person-years, 95% CI = 5.4–9.6) was 
significantly higher than in women (3.1cases/1000 person-years, 95% CI = 2.2–4.5), but in presence of dysglyce-
mia, both incidence (32.1cases/1000 person-years, 95% CI = 21.7–45.8 in men vs 40.4 cases/1000 person-years, 
95% CI = 30.1–53.2 in women) and adjusted OR (3.5 (1.9–6.2) in men vs 12.4 (7.1–21.8) in women, were higher 
in women than in men.
Discussion
The incidence of diabetes was determined by means of a representative sample of the Spanish population and 
using the best available diagnostic methods (OGTT and/or HbA1c). The overall incidence adjusted for the 
Spanish population, and calculated taking into account that not all subjects underwent all diagnostic tests, was 
of 11.6 cases/1000 person-years. The incidence of known diabetes has only been a fraction of the total diabetes 
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detected: 3.71 cases/1000 person-years, a figure that can be assimilated to the incidence of diabetes diagnosed in 
the national health system.
In Spain, current data about incidence of diabetes in the general population are scarce and partial. In 
the Lejona study, performed in the north of Spain in 1995, the incidence of diabetes was of 8.2 cases/1000 
person-years 10-year prospective study on the incidence10. In 2008, the revaluations of two local studies were 
completed, one in the north (Asturias Study)11 and another one in the south (Pizarra study)12 of Spain. In both of 
them, approximately 700 subjects were followed for an average of 6–7 years. Both studies were conducted with a 
very similar methodology, but the incidence in the north was of 10.8 cases/1,000 person-years and in the south 
of 19.1 cases/1,000 person-years. One possible reason for the apparent disparity in the results of these two stud-
ies, practically contemporaneous, could be the higher prevalence and incidence of obesity in the population of 
Pizarra, where the mean weight gain during the follow-up doubled the one of the Asturias study11,12. The results 
that we present from the di@bet.es cohort are concordant with the studies carried out in the north, but lower than 
those carried out in the south of Spain. In our cohort, the diabetes prevalence has been previously shown to be 
higher in the south of Spain compared to the other parts of the country11.
Non- participants Participants pa
n 1189 2408
Sex (%male) 43.7 39.7 0.01
Age (years) 46.7 ± 16.5 47.9 ± 14.7 0.03
BMI (kg/m2) 27.6 ± 5.2 27.5 ± 4.7 0.7
Systolic blood pressure (mmHg) 128.6 ± 19.2 128.7 ± 18.5 0.8
Dyastolic blood pressure (mmHg) 76.2 ± 12.6 76.3 ± 10.4 0.7
Fasting glucose (mmol/L) 5.04 ± 0.7 5.1 ± 0.7 0.008
Post OGTT Glucose (mmol/L) 5.8 ± 1.7 5.7 ± 1.7 0.4
Waist (cm) 92.4 ± 14.2 92.2 ± 13.1 0.6
Family history of diabetes (%)
   No 54.8 49.8
0.009   Yes, one relative 25.5 26.7





Mediterranean diet score (14p)
   <8p 68.4 64.4
0.02




  Former smoker 19.1 24.4
  Current smoker less than 15 cig/day 15.5 14.5
  Current smoker more than 15 cig/day 16.4 11.4
   Dyslipidaemia (%) 25.7 26.6 0.5
   Obesity (%) 28.1 26.2 0.1
   Central obesity (%) 66.0 70.0 0.004











   High school 23.9 23.6
   College 16.8 17.6
Table 1. Main characteristics of the population in the cross-sectional study. Comparison between participants 
and non-participants in the follow-up. ap = signification level of t-student, Mann-Whitney or chi2 test 
according to type of variable.
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In 2013, data on the incidence of diabetes from the Spanish participants in the EPIC cohort, made up of volun-
tary donors from several Spanish localities followed for 12 years, were published13. Adjusted rates varied between 
4.2 and 7.2 cases/1000persons-year in men and 3.5 and 4.3 cases/1,000 person-years in women, with abdominal 
obesity being one of the main risk factors. These lower incidence rates with respect to population-based studies 
may be due to the sample selection, since the EPIC comprised healthy volunteers (blood donors and workers), 
while in the other Spanish studies, including the present results, sampling was composed of general population, 
not necessarily healthy. The diagnosis of diabetes by OGTT also increases the number of incident cases. The wide 
population studies that use this diagnostic tool are very scarce. Something similar happens with the study based 
on the working population recently published in Spain “Incidence of Diabetes in the Working Population in 
Spain”14: the incidence (5.0 cases/1000 person-years) was very low and similar to the one found in EPIC and other 
studies in which the working population was mainly involved.
There are no studies on the incidence of diabetes in Europe as a whole, and only few countries have data at 





Incidence rate per 1000 
person-years (95% CI) ORa (95% CI) ORb (95% CI)
All sample 2408 156 18088 8.6 (7.3–10.1) — —
Sex
  Women 1451 81 10883 7.4 (5.9–9.3) Ref. cat. Ref. cat.
  Men 957 75 7205 10.4 (8.2–13) 1.5 (1.1–2.1) 2.7 (1.6–4.5)
OGTT result
  Normoglycemia 2115 75 15892 4.7 (3.7–5.9) Ref. cat. Ref. cat.
  Isolated IGT 154 35 1156 30.3 (21.1–42.1) 10.8 (5.7–20.2) 7.9 (4–15.5)
  Isolated IFG 102 27 761 35.5 (23.4–51.6) 14.4 (7.5–27.6) 11.7 (5.9–23.3)
  Combined IFG-IGT 37 19 278 68.3 (41.1–106.6) 42.3 (16.3–109.5) 48.8 (17.1–139.8)
  P for trend <0.0001 <0.0001
Obesity
  BMI < 25 kg/m2 749 15 5628 2.7 (1.5–4.4) Ref. cat. Ref. cat.
  BMI 25–30 kg/m2 1018 57 7662 7.4 (5.6–9.6) 1.9 (0.9–3.9) 1.2 (0.6–2.3)
  BMI ≥ 30 kg/m2 626 82 4691 17.5 (13.9–21.7) 4.6 (2.3–9.2) 2.3 (1.1–4.6)
  P for trend <0.0001 <0.0001
Central obesity (Waist ≥94 cm in men and ≥80 cm in women)
  No 718 8 5400 1.5 (0.6–2.9) Ref. cat. Ref. cat.
  Yes 1677 146 12596 11.6 (9.8–13.6) 10.6 (2.6–43.5) 3.4 (1.5–7.8)
Family History of diabetes (first-degree relatives)
  No 1569 73 11794 6.2 (4.9–7.8) Ref. cat. Ref. cat.
  Yes 839 83 6294 13.2 (10.5–16.3) 2.4 (1.5–3.9) 2.3 (1.6–3.3)
Table 2. Incidence of diabetes according to the main exposure factors present in the cross-sectional study. aORs 
were calculated for each variable by logistic regression adjusted for age and sex (sex was adjusted for age). bORs 
were calculated using a single logistic regression model (all variables listed are introduced in the analysis at 
once) and additionally adjusted for presence of high blood pressure, level of physical activity (IPAQ), education 
level, and Mediterranean diet score. Ref. cat. = Reference category.
Figure 1. Incidence of diabetes according to sex and age, adjusted for diagnostic method.
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incidence of 4.2 per 1000 person-years, or the study by Holst6 in Denmark, with incidences of 6.2 in men and 4.4 
in women, are examples of this, but their findings are clearly lower than those of our study. The IDF estimates that 
the prevalence of diabetes in Europe will increase by 16% between 2017 and 20459. This estimate is equivalent to 
an incidence rate of 4.2 cases/1000 person-years, similar to the one calculated for diagnosed diabetes by health 
systems that do not usually use OGTT as a diagnostic method. The incidence of diabetes in these works is similar 
to the incidence of previously known diabetes in our study (3.7 cases/1000 person-years).
The studies conducted in Europe (mostly local) in the last years, based on glucose determinations and rarely 
using OGTT, reveal the heterogeneity of diabetes incidence among the different studies14–22 ranging from 5 per 
1000 cases of the ICARIA study14 in working population, to more than 17 per 1000 of the Hoorn study18 with 
OGTT in a population with mean age around 60 years old. These differences may be due to (besides the meth-
odology) the important differences between countries in the prevalence of obesity, physical activity, or eating 
patterns, which might partially explain the variation in diabetes prevalence23. On the other hand, our incidence 
rates are clearly lower than those reported for high risk populations, like the North-american19,24.
In the di@bet.es study, the variables associated with the presence of diabetes in the cross-sectional study were 
age, sex, educational level, obesity, abdominal obesity, hypertension, low levels of HDL cholesterol, and high lev-
els of triglycerides as well as the family history of diabetes4. In the current work, most of these variables are also 
associated with incident diabetes, except for hypertension and dyslipidemia. This may be due to the fact that these 
variables are not causative of diabetes, but they rather share a common pathophysiology, probably linked to the 
loss of insulin sensitivity25. The main predictor variable has been the presence of dysglicemia in the baseline study, 
as it happened in other studies14,17,18,26. The presence of IGT conferred a lower risk than IFG, while the combina-
tion of both multiplied the risk of developing diabetes, especially in women. A similar effect has been found in the 
ADDITION-Denmark study26. The importance of detecting an early dysglicemia lies not only in the increased 
risk of developing diabetes over time, but also in the higher risk of developing cardiovascular and renal disease, 
and the higher mortality than normoglycemic subjects27. In our work, the risk associated with the presence of IGT 
or IFG is somewhat higher than the one described in the meta-analysis by Gerstein28.
Important differences have been found in the prevalence and incidence of diabetes according to sex3. In 
women, the incidence rates were lower than in men, but only in normoglycemic women. However, the presence 
of dysglycemia increased much more the risk in women that became statistically equal to men, and resulted 
in a significantly higher OR (significant interaction disglycemia x sex), which, as far as we know, has not been 
described in other studies.
The ability of glucose post-OGTT to predict diabetes, together with its relationship with mortality and car-
diovascular risk29, makes it one of the main risk factors to be taken into account, although the complexity of its 
measurement makes it an invalid test for screening. In our study, glucose post OGTT predicted the risk of dia-
betes incidence, and, as already mentioned, its simultaneous alteration with basal glycemia multiplied the risk.
Overall and central obesity were independently associated with diabetes. It has been shown30 that, from a 
certain age, obesity is associated with a reduction in the years of life free of diabetes and an increase in the years 
lived with diabetes.
The adjustment of the models with the family history of diabetes, the presence of high blood pressure, the 
adherence to the Mediterranean diet, or the intensity of physical exercise hardly modify the magnitude of the 
OR of the models adjusted only for age and sex. In our study, we did not find a direct effect of adherence to the 
Mediterranean diet and the level of physical activity on the incidence of diabetes. This may possibly be due to the 
limited sample size or the lack of precision of some variables as synthetic as the ones used.
The strengths of this study are that the sample has been chosen randomly from all over Spain, with people 
aged 18 and over, most of whom underwent an OGTT to diagnose diabetes. In the follow-up, HbA1c was also 
used, which guarantees the capture of most of the incident diabetes. Most published studies on diabetes incidence 
perform incidence estimates based on health records or self-reported diabetes and therefore may underestimate 
the real incidence of diabetes5,6,26,31,32.
Some limitations deserve mention. Our sample is composed of white people and, therefore, it cannot be gen-
eralised to other ethnic groups. The participation in the follow-up was of 66%, however, we have found few 
differences between people who participated in the follow-up and those who did not, and as a result, the possible 
participation bias has been minimal. Moreover, diabetes incidence in Spain may not be representative of other 
countries due to different dietary habits, physical exercise, or genetic background, although these variables have 
much less influence on the risk of diabetes than the presence of obesity or previous dysglycemia.
Spain has one of the highest life expectancies in the world (only less than Japan and Switzerland) and one of 
the lowest cardiovascular disease mortality rates in Europe, despite the high rates of metabolic diseases (obesity, 
diabetes, or hypertension) found in this and other studies33. This apparent paradox can be explained by the inter-
action between the genetic variants selected over centuries in the Mediterranean area with changes in current 
lifestyles (abandonment of the Mediterranean diet and sedentary lifestyle)34, issues that need additional research 
to be answered.
In conclusion, this work provides data about population-based rates of diabetes incidence and associated risk 
factors in a nation-wide cohort from Spanish population.
Methods
Study design, setting and population. The di@bet.es epidemiological trial is a population based cohort 
study. The initial cross-sectional study was undertaken between 2008 and 2010 using a random cluster sampling 
of Spanish population4. The sample size was calculated assuming a diabetes prevalence of 15% of the population, 
with an error lower than 1%. The di@bet.es study sample consisted of 5072 subjects older than 18 years, randomly 
selected from the National Health System registries distributed into 100 clusters (primary health care centres). 
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Exclusion criteria in the cross-sectional study were: serious illness, pregnancy, recent delivery or lactation, sur-
gery within the previous month, or any other disabling situation that prevented participation.
The cohort was re-evaluated in 2016–17 (follow-up time was 7.5 ± 0.6 years). All subjects who had completed 
the baseline study (n = 5072) were invited by letter and by phone to attend another clinical examination. The 725 
subjects who had diabetes at baseline were excluded from all the incidence calculations. Thus, the at-risk sample 
included 4347 people. As with the cross-sectional study, people with serious illness, pregnancy, recent delivery 
or lactation, or surgery within the previous month were excluded. Finally, 2408 subjects completed the follow-up 
(Fig. 2).
The research was carried out in accordance with the Declaration of Helsinki (2008) of the Word Medical 
Association. Both the cross-sectional study and the follow-up study were approved by the Ethics and Clinical 
Research Committee of the Hospital Regional Universitario de Malaga (Malaga, Spain). All the participants were 
informed about the nature of the study and provided written informed consent in the two phases of the study, 
document approved by the committee mentioned above.
procedures. The participants were invited to attend a single examination visit at their health centre with a 
nurse specially trained for this project. Information was collected using an interviewer-administered structured 
questionnaire, followed by a physical examination, blood sampling, and an oral glucose tolerance test (OGTT).
A structured questionnaire included closed questions was used to collect the following data: sex, age, instruc-
tion level (none, basic, high school or college), personal history of diabetes (yes/no), high blood pressure (yes/no) 
and dyslipidemia (yes/no), family history of diabetes (yes/no), medications, specifically asking about diabetes, 
high blood pressure or dyslipidemia medication; frequency of food consumption, and physical activity.
The physical examination included measurement of body weight, height, and waist and hip circumferences 
that were performed using standardised methods35. Besides, body mass index (BMI = weight/height2), and waist 
to hip ratio (WHR) were calculated. Blood pressure was measured with the subject seated after 5 minutes of rest 
and 2 minutes after the first measurement. A third measure was performed if there was a difference greater than 
10% between the first two measurements.
Participants with baseline capillary blood glucose levels lower than 7.8 mmol/L (measured by OneTouch® sys-
tem, Lifescan, Johnson & Johnson, S.A., Madrid), and not receiving treatment for diabetes, underwent a standard 
oral glucose tolerance test (OGTT) with 75 g of glucose dissolved in 200 ml of water. In this way, fasting and 2 h 
venous samples were obtained (8 to 10 hours fasting samples were obtained between 8:30am and 10:00 am in gel 
tubes suitable with a vacuum blood extraction system), the samples were allowed to stand for 30′. After centrifu-
gation, the serum was separated from the clot and frozen (in cross-sectional study) or refrigerated (in follow up). 
All samples were analyzed in the same central laboratory after shipment through a specialized courier (Cerba 
International Laboratory in Barcelona) in the cross-sectional study, and the General Laboratory of the Hospital 
Regional Universitario of Malaga in the follow-up). In both stages, glucose was determined by the hexokinase 
enzymatic method, total cholesterol by cholesterol oxidase enzymatic method, HDL cholesterol by direct method, 
triglycerides by glycerol phosphate oxidase enzymatic method, LDL cholesterol was calculated by Friedewald 
formula. HbA1C by high-performance liquid chromatography (analyzer ADAMS A1C HA-8180V, ARKRAYR) 
were measured only in follow up study.
The samples were deposited in the Biobank of the Hospital Regional Universitario de Malaga-IBIMA, which 
belongs to the Andalusian Public Health System Biobank, and the biorepository CIBERDEM managed by 
IDIBAPS Biobank (Barcelona, Spain).
In follow up, people who did not want to fully participate in the complete study were asked to take a short 
survey in order to collect information about the drugs they were taking (to determine the existence of clinical 
diabetes, hypertension or dyslipidemia in treatment), if they were on some type of diet, and self-reported weight.
Figure 2. Participation flow chart.
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Assessment of outcomes in follow up. Incident diabetes was defined as fasting serum glucose equal or 
higher than 7 mmol/L or 2 hour post load serum glucose equal or higher than 11 mmol/L or HbA1c equal or higher 
than 6.5% (47.54 mmol/molHb) or use of glucose-lowering medication at the follow-up examination36. “Known 
diabetes” was established when the subject reported having diabetes and/or being treated with diabetes drugs.
Main risk/exposure factors. The following variables from cross-sectional study were considered: first, glu-
cose impairment category in the cross-sectional study: subjects were classified according to their blood glucose as 
having a normal OGTT or impaired fasting glucose (IFG) or impaired glucose tolerance (IGT), or both following 
Alberti and Zimmet37. Second, obesity (BMI equal or higher than 30 kg/m2) or overweight (BMI between 25 and 
30 kg/m2). Third, central obesity presence defined as waist circumference >94 cm in men or >80 cm in women38.
Secondary exposure factors and potential confounders. The following variables from cross-sectional 
study were recorded: age, educational level (none, basic, high school or college), physical activity by the 
International physical activity questionnaire (IPAQ)39, smoking (current, ex- or never smoker), high blood 
pressure (blood pressure equal or higher 140/90 mmHg or receiving antihypertensive treatment), dyslipidemia 
(triglycerides were equal or higher 1.7 mmol/L or HDL cholesterol less than 1.03 mmol/L in men or less than 
1.29 mmol/L in women or medication), and family history of diabetes (at least one first degree relative with dia-
betes). A qualitative food frequency questionnaire was administered face-to-face by a trained dietitian40. Annual 
frequency consumption of 50 food items was specified in 11 different categories as follows: never/seldom, 1 and 
2–3 times/month, 1, 2–3 and 4–6 times/week and 1, 2, 3, 4 and >4 times/day, and a 14-point Mediterranean diet 
score was calculated.
Statistical analysis. Data are presented as means ± SD, or proportions. Differences in baseline variables 
according to participation in follow-up were determined by the t-test for independent samples, the Mann- 
Whitney test, or chi2 test when appropriate. The sample incidence rates (IRs) were calculated as number of events/
person-time at risk for diabetes, assuming a constant incidence over time. The estimation of the population inci-
dence rate was calculated taking into account that not all the participants were diagnosed with the four possible 
criteria (previous diabetes diagnosed after the cross-sectional study, fasting glucose, postload glucose or HbA1c) 
and adjusted for sex and age by direct method using as reference the Spanish population (https://www.ine.es/, 
accessed June 2009).
Multivariate analysis was performed using logistical regression for odd ratios (ORs) calculation adjusted for 
potential confounders. The test of Hosmer and Lemeshow was used to check the goodness of fit. For IRs and ORs, 
95% confidence intervals were computed. Analyses were made using SPSS v20 (IBM., Chicago, IL, USA).
Data availability
The datasets generated during and/or analyzed during the current study are available from the corresponding 
author on reasonable request.
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